What does FDA-Inspected mean?

It means the US FDA has conducted at least one inspection of the facility - pre-approval, surveillance, or for-cause. The outcome categories are: NAI (No Action Indicated), VAI (Voluntary Action Indicated), or OAI (Official Action Indicated). FDA inspection records are tracked publicly via the FDA Inspections Database and 483/Warning Letter releases. A clean inspection record is a strong external signal of regulatory readiness for US-bound product.

Which European countries have the most FDA-inspected biotech facilities?

Switzerland and Germany dominate - pharma majors (Roche, Novartis, BioNTech, Bayer) maintain dense FDA inspection records across multiple sites. Denmark (Novo Nordisk, Lundbeck) and Sweden (AstraZeneca) carry significant FDA-inspected manufacturing. Lithuania (Northway/Biotechpharma) and Poland (Polpharma) have FDA-inspected CDMO and finished-dose facilities. Smaller markets typically rely on a single FDA-inspected site for US-bound supply.

Why does FDA inspection matter for European companies?

For European pharma and CDMO operators selling into the US, FDA inspection is the practical gate to commercial supply. Without a passed FDA inspection, a foreign facility cannot be cleared for US drug import under most pathways. For diligence buyers, an FDA-inspected European site signals (a) the operator already meets a higher external quality bar than EU GMP alone, and (b) the facility can be relied on for US-bound contracts without re-qualification overhead.

How are FDA-inspected companies verified in this directory?

Every profile is hand-reviewed: the FDA-Inspected marker requires evidence from a primary source - an FDA Inspections Database record, an FDA-issued 483 or NAI/VAI/OAI letter, an FDA-published warning or compliance action notice, or operator documentation referencing a specific FDA inspection. Self-claimed FDA inspection without traceable documentation does not earn the marker.

Compliance filter

FDA-Inspected biotech companies in Europe - compliance directory

FDA inspection means the US Food and Drug Administration has audited a manufacturing or testing facility against US regulations - typically GMP for drugs (21 CFR 210/211), Quality System Regulation for devices (21 CFR 820), or GLP for nonclinical (21 CFR 58). For European facilities, an FDA inspection record signals that the site can supply the US market under existing approvals or has demonstrated US-grade compliance during a regulatory review. This page lists European biotech, pharma, and CDMO facilities with publicly documented FDA inspection markers - a non-trivial filter for diligence buyers, US-bound supply chain teams, and licensors.

Evidence

Visible records15

Verified15

Countries covered8

Categories7

Avg sources / record2.7

Compliance view

Where is this standard strongest?

Finland (5), Germany (3), Sweden (2), and Denmark (1). Top cities: Turku, Finland (3), Kuopio, Finland (2), Copenhagen, Denmark (1), and Epalinges, Switzerland (1). Most visible records: ADC Therapeutics SA, altona Diagnostics GmbH, Bayer Oy Turku Product Supply Center, and BioSpring GmbH.

Compliance view

Which categories carry this standard?

CDMO (4), Diagnostics (4), Therapeutics (2), and Manufacturing (2). Latest review: 24 April 2026. Review cycle: April 2026.

Compliance view

Why this standard matters

This page helps separate vague claims from records where the quality or regulatory marker is already visible in public evidence.

Compliance view

Related market brief

How biologics manufacturing, drug discovery, and pharmaceutical logistics connect across Germany, Poland, and the Baltics - with named companies and routes you can actually use.

Open related brief

Country breakdown

FDA-Inspected companies by country

Count of companies with FDA-Inspected-relevant quality systems, the strongest city in each country, and a sample operator you can open as an entry point.

Country	Companies	Top city	Sample operator
Finland	5	Turku	3PBIOVIAN
Germany	3	Laupheim	Rentschler Biopharma
Sweden	2	Uppsala	Biotage AB
Denmark	1	Copenhagen	Zealand Pharma
Latvia	1	Riga	Institute of Organic Synthesis
Lithuania	1	Vilnius	Thermo Fisher Supply Vilnius
Norway	1	Lindesnes	GE HealthCare Lindesnes
Switzerland	1	Epalinges	ADC Therapeutics SA

Category breakdown

FDA-Inspected companies by category

Categories carrying FDA-Inspected-relevant quality systems, their count, and the strongest sample operator in each.

Category	Companies	Sample operator
CDMO	4	3PBIOVIAN
Diagnostics	4	Bone Index Finland Ltd.
Therapeutics	2	ADC Therapeutics SA
Manufacturing	2	Bayer Oy Turku Product Supply Center
Research	1	Institute of Organic Synthesis
Infrastructure anchor	1	Thermo Fisher Supply Vilnius
Tools	1	Biotage AB

Full list

FDA-Inspected records

15 compliance records currently match the active filter.

Epalinges-based NYSE-listed (ADCT) antibody-drug conjugate company, with FDA-approved Zynlonta (loncastuximab tesirine) for diffuse large B-cell lymphoma and a broader oncology ADC pipeline.

Lead: Ameet MallikChief Executive Officer
Scale: Commercial ADC oncology

Hamburg ISO 13485-certified molecular diagnostics manufacturer building CE-IVD real-time PCR assays for infectious disease, with global distribution through subsidiaries and a historical FDA EUA track record for its RealStar Ebolavirus assay.

Lead: Soenke FriedrichsenManaging Director (joint with Hans Kuhn)
Scale: Commercial CE-IVD diagnostic manufacturing

Turku pharmaceutical manufacturing site producing hormonal IUDs (Mirena, Kyleena, Jaydess) for Bayer's global contraceptive portfolio, with a disclosed 250 million EUR automated plant expansion opened in 2025.

Lead: Tomi PenttilaHead of Bayer Product Supply Center, Turku
Scale: Commercial specialty pharmaceutical manufacturing

Frankfurt-based oligonucleotide CDMO producing antisense oligonucleotides, siRNA, guide RNA and mRNA at research-to-commercial scale, with a documented cGMP track record since 2007 and FDA-inspected commercial supply since 2020.

Lead: Sylvia WojczewskiCo-Founder and Chief Executive Officer
Scale: Research through multi-kilogram commercial oligonucleotide API

Kuopio medical-device company developing the Bindex point-of-care pulse-echo ultrasound for osteoporosis diagnosis, FDA 510(k)-cleared and CE-marked.

Lead: Janne KarjalainenChief Executive Officer
Scale: Medical-device manufacturing

Norway's largest pharmaceutical manufacturing site, producing bulk iohexol and iodixanol API for GE HealthCare's global iodinated contrast-media business from a 100-acre integrated chemical campus operating since 1974.

Lead: Peter J. ArduiniPresident and CEO, GE HealthCare Technologies (global)
Scale: Bulk API manufacturing for global contrast-media supply

Turku IVD manufacturing and diagnostics R&D site, developing neonatal and prenatal screening assays (DELFIA, AutoDELFIA) and global newborn-screening instruments; now part of Revvity (Wallac Oy legal entity continues).

Lead: Petra FuruGeneral Manager, Reproductive Health (Turku)
Scale: Commercial IVD manufacturing

Kuopio gene-therapy CDMO and viral-products manufacturer operating cGMP production, drug-substance and drug-product suites, and a growing pharma campus in Savilahti.

Lead: Matthias KriegerManaging Director
Scale: Clinical-to-commercial gene-therapy manufacturing

Turku biologics and viral-vector CDMO site offering microbial proteins, plasmid DNA, viral vectors, aseptic fill-finish, and QC services under EMA-certified and FDA-inspected GMP operations.

Lead: Damaso MoleroChief Executive Officer
Scale: Investigational to commercial GMP manufacturing

Vilnius supply node for Thermo Fisher's cell-culture and CTS input chain supporting Baltic biologics and advanced-therapy workflows.

Lead: Verification pendingVilnius site lead - under review
Scale: Global life-science supply node

Laupheim biologics CDMO anchor focused on mammalian production, late-stage development, and regulated commercial manufacturing.

Lead: Prof. Dr. Uwe BüchelerInterim Chief Executive Officer
Scale: Clinical-to-commercial CDMO manufacturing

Uppsala life-science tools company building purification, synthesis, and analytical workflow systems for drug discovery, peptide chemistry, and sample preparation labs.

Lead: Frederic VanderhaegenChief Executive Officer
Scale: Industrial Tools

Copenhagen-area peptide therapeutics company focused on obesity, metabolic disease, and specialty indications through discovery and late-stage development.

Lead: Adam SteensbergPresident and Chief Executive Officer
Scale: Global Biopharma

Riga medicinal-chemistry and drug-discovery institute combining synthetic chemistry, pharmacology, process research, and translational infrastructure inside Latvia's strongest chemistry campus.

Lead: Dace KārkleDirector
Scale: Discovery / Pilot

Gothenburg reproductive-health headquarters and production base combining IVF media, time-lapse imaging, and genomics-linked product operations inside the Vitrolife Group.

Lead: Bronwyn BrophyChief Executive Officer
Scale: Global Market

FAQ

Frequently asked questions

What does FDA-Inspected mean?: It means the US FDA has conducted at least one inspection of the facility - pre-approval, surveillance, or for-cause. The outcome categories are: NAI (No Action Indicated), VAI (Voluntary Action Indicated), or OAI (Official Action Indicated). FDA inspection records are tracked publicly via the FDA Inspections Database and 483/Warning Letter releases. A clean inspection record is a strong external signal of regulatory readiness for US-bound product.
Which European countries have the most FDA-inspected biotech facilities?: Switzerland and Germany dominate - pharma majors (Roche, Novartis, BioNTech, Bayer) maintain dense FDA inspection records across multiple sites. Denmark (Novo Nordisk, Lundbeck) and Sweden (AstraZeneca) carry significant FDA-inspected manufacturing. Lithuania (Northway/Biotechpharma) and Poland (Polpharma) have FDA-inspected CDMO and finished-dose facilities. Smaller markets typically rely on a single FDA-inspected site for US-bound supply.
Why does FDA inspection matter for European companies?: For European pharma and CDMO operators selling into the US, FDA inspection is the practical gate to commercial supply. Without a passed FDA inspection, a foreign facility cannot be cleared for US drug import under most pathways. For diligence buyers, an FDA-inspected European site signals (a) the operator already meets a higher external quality bar than EU GMP alone, and (b) the facility can be relied on for US-bound contracts without re-qualification overhead.
How are FDA-inspected companies verified in this directory?: Every profile is hand-reviewed: the FDA-Inspected marker requires evidence from a primary source - an FDA Inspections Database record, an FDA-issued 483 or NAI/VAI/OAI letter, an FDA-published warning or compliance action notice, or operator documentation referencing a specific FDA inspection. Self-claimed FDA inspection without traceable documentation does not earn the marker.

Next step

Read the compliance filter, then move into cities and categories.

This page works best as a starting filter. For deeper comparison, use city, category, and methodology pages.

Open strongest city Open strongest category Open methodology Suggest a company

FDA-Inspected biotech companies in Europe - compliance directory

Where is this standard strongest?

Which categories carry this standard?

Why this standard matters

Related market brief

FDA-Inspected companies by country

FDA-Inspected companies by category

FDA-Inspected records

ADC Therapeutics SA

altona Diagnostics GmbH

Bayer Oy Turku Product Supply Center

BioSpring GmbH

Bone Index Finland Ltd.

GE HealthCare Lindesnes

Wallac Oy (Revvity)

FinVector

3PBIOVIAN

Thermo Fisher Supply Vilnius

Rentschler Biopharma

Biotage AB

Zealand Pharma

Institute of Organic Synthesis

Vitrolife Group

Frequently asked questions

Read the compliance filter, then move into cities and categories.